GF Fund Management CO. LTD. Takes Position in Insmed Incorporated (NASDAQ:INSM)

GF Fund Management CO. LTD. bought a new stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 3,756 shares of the biopharmaceutical company's stock, valued at approximately $259,000.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after buying an additional 1,075,796 shares in the last quarter. Darwin Global Management Ltd. raised its stake in shares of Insmed by 23.5% in the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after buying an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Insmed by 1.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company's stock valued at $877,113,000 after buying an additional 123,429 shares in the last quarter. Capital International Investors raised its stake in shares of Insmed by 9.1% in the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after buying an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Insmed by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after purchasing an additional 273,759 shares during the last quarter.

Insmed Trading Up 0.4%

Shares of NASDAQ INSM traded up $0.30 during mid-day trading on Friday, hitting $69.51. The company's stock had a trading volume of 774,098 shares, compared to its average volume of 2,166,842. The stock has a market cap of $12.66 billion, a price-to-earnings ratio of -12.47 and a beta of 0.84. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a one year low of $53.69 and a one year high of $84.91. The company's fifty day simple moving average is $69.77 and its 200-day simple moving average is $72.92.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The business had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period last year, the business posted ($1.06) EPS. On average, sell-side analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of recent analyst reports. Jefferies Financial Group began coverage on shares of Insmed in a research report on Tuesday, May 13th. They issued a "buy" rating and a $105.00 price target on the stock. UBS Group dropped their price target on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. Guggenheim reiterated a "buy" rating and issued a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Wells Fargo & Company raised their price objective on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. Finally, Morgan Stanley raised their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $96.73.

Insider Activity at Insmed

In related news, Director Clarissa Desjardins purchased 1,130 shares of Insmed stock in a transaction dated Wednesday, May 21st. The stock was bought at an average price of $66.35 per share, for a total transaction of $74,975.50. Following the completion of the acquisition, the director now directly owns 3,025 shares of the company's stock, valued at $200,708.75. This represents a 59.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO William Lewis sold 18,750 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $77.03, for a total transaction of $1,444,312.50. Following the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $25,742,347.58. The trade was a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 153,098 shares of company stock worth $10,724,192. 3.00% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.